Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Bukwang Pharmaceutical Co. Ltd.

Headquarters: Seoul, South Korea
Year Founded: 1960
Status: Public
Industry Sector: HealthTechnology
CEO: Woo-Hyun Lee, MBA; Hee-Won Yoo
Number Of Employees: 582
Enterprise Value: $178,950,969
PE Ratio: -93.04
Exchange/Ticker 1: KRX:003000
Exchange/Ticker 2: N/A
Latest Market Cap: $167,658,656

BioCentury | Jan 21, 2022
Emerging Company Profile

ImmPACT: uniting CAR T platforms for ‘logic-gate’ therapies

Los Angeles-area biotech has $111M series B, early clinical data in hand as it advances bispecific CAR T
BioCentury | Jul 7, 2017
Company News

Acer finds public path via Opexa merger

BioCentury | Jul 3, 2017
Company News

Acer finds public path via Opexa merger

BioCentury | Mar 15, 2017
Clinical News

Apatinib: Ph III ANGEL started

BioCentury | Jun 27, 2016
Clinical News

MLR-1023: Phase IIa data

BioCentury | May 16, 2016
Financial News

Acer Therapeutics completes venture financing

BioCentury | Mar 21, 2016
Finance

Multiples in Korea

Why big venture returns on Korea's Qurient is likely an exception
BioCentury | Apr 13, 2015
Clinical News

MLR-1023: Phase IIa started

BioCentury | Nov 24, 2014
Company News

Melior, Bukwang deal

Items per page:
1 - 10 of 24
Help Center
Username
Request a Demo
Request Training
Ask a Question